½ÃÀ庸°í¼­
»óǰÄÚµå
1780324

°¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2021-2031³â) : ¼¼°è ¹× Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® - ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°

Infectious Disease In vitro Diagnostics Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Application, End User, and Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 190 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ±Ô¸ð´Â 2024³â 456¾ï 9,000¸¸ ´Þ·¯¿¡¼­ 2031³â¿¡´Â 767¾ï 1,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, 2025-2031³â CAGRÀº 7.7%·Î ¿¹ÃøµË´Ï´Ù. °¨¿°º´ À¯Çà Áõ°¡¿Í ÁÖ¿ä ±â¾÷ÀÇ Àü·«Àû °³¹ßÀº °¨¿°º´ ü¿ÜÁø´ÜÁ¦ ½ÃÀå ±Ô¸ð È®´ë¿¡ ±â¿©ÇÏ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ ¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª ºÒÃæºÐÇÑ »óȯ ½Ã³ª¸®¿À°¡ °¨¿°¼º ü¿ÜÁø´Ü ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

ºÐÀÚÁø´Ü¾à°ú ÀÚµ¿È­ ½Ã½ºÅÛÀÇ °³¹ß ¹× ÅëÇÕÀ» Æ÷ÇÔÇÑ ±â¼ú ¹ßÀüÀº °¨¿°¼º Áúȯ °ËÃâÀÇ Á¤È®¼º, ¼Óµµ, Á¢±Ù¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¾Æ·¡´Â ±× ÇÑ ¿¹ÀÌ´Ù:

2024³â 6¿ù, MP Biomedicals´Â Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®, »ì¸ð³Ú¶ó, ÄÝ·¹¶ó±Õ¿¡ ´ëÇÑ ½Å¼ÓÇÑ ¸é¿ªÅ©·Î¸¶Åä±×·¡ÇÇ ºÐ¼®ÀÇ »õ·Î¿î ¶óÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù.

2024³â 6¿ù, ·Î½´´Â SARS-CoV-2, ÀÎÇ÷翣ÀÚ A/B, RSV¸¦ µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖµµ·Ï ¾÷µ¥ÀÌÆ®µÈ cobas liat multiplex PCR panelÀÇ FDA ±ä±Þ»ç¿ë½ÂÀÎ(EUA)À» ȹµæÇÏ¿© 20ºÐ À̳»·Î Áõ»ó È£Èí±â °¨¿°ÁõÀ» °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

2024³â 7¿ù, ¼È·Ï ¹ÙÀÌ¿À»çÀ̾𽺴 2025³â Ãâ½Ã¸¦ ¸ñÇ¥·Î 2024³â 5¿ù¿¡ CRISPR ±â¹Ý ÀÓÁú ¹× Ŭ¶ó¹Ìµð¾Æ ÀϹÝÀǾàǰ(OTC) °Ë»ç¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇß½À´Ï´Ù. ¶ÇÇÑ AI¿Í ³ª³ëÅ×Å©³î·¯ÁöÀ» ÅëÇÑ ¸Ó½Å·¯´×À» ÅëÇÕÇÑ APEX-TBµµ Ãâ½ÃµÇ¾î ÈÞ´ë¿ë ±â±â¸¦ ÀÌ¿ëÇÑ Á¤È®ÇÑ ½Ç½Ã°£ ºÐÀÚÁø´ÜÀ» Á¦°øÇÕ´Ï´Ù.

2024³â 6¿ù, QIAGENÀº µðÁöÅÐ PCR(dPCR) Ç÷§Æû QIAcuity¿¡ 35Á¾ÀÇ ½À½Ä ½ÇÇè½Ç Å×½ºÆ®¸¦ °ÅÄ£ µðÁöÅÐ PCR ¹Ì»ý¹° DNA °ËÃ⠺м®¹ýÀ» »õ·Î µµÀÔÇÏ¿© ¹Ì»ý¹° ¿¬±¸ ¿ª·®À» ´ëÆø °­È­Çß½À´Ï´Ù.

ÀÌ·¯ÇÑ ¹ßÀüÀº °¨¿°º´ Ä¡·áÀÇ ¹Ì·¡¸¦ À̲ø ºÐ»êÇü, »ç¿ëÀÚ Áß½É, ºü¸¥ Áø´Ü ±â¼úÀ» ÇâÇÑ Å« ¿òÁ÷ÀÓÀÇ ÀϺÎÀÔ´Ï´Ù. ÀÌ´Â ÇâÈÄ ¼ö³â°£ °¨¿° ü¿ÜÁø´Ü ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº° ÀλçÀÌÆ®

°¨¿° ü¿ÜÁø´Ü ½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚº°·Î º´¿ø ¹× Ŭ¸®´Ð, Áø´Ü¿¬±¸¼Ò, Ç÷¾×ÀºÇà, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2024³â °¨¿°¼º ü¿ÜÁø´Ü ½ÃÀå Á¡À¯À²Àº º´¿ø ¹× Ŭ¸®´ÐÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. ¶ó½Î¿­, ÄÝ·¹¶ó, °áÇÙ, ¸»¶ó¸®¾Æ µîÀÇ ºó¹øÇÑ ¹ß»ýÀ¸·Î º´¿ø ¹× Áø·á¼Ò¿¡¼­ Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´ÜÀÇ Çʿ伺ÀÌ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ ¼ö°¡ ±ÞÁõÇÏ°í ¾çÁúÀÇ ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó º´¿øÀº ºÐÀÚÁø´Ü¹ýÀ» Æ÷ÇÔÇÑ º¸´Ù Áøº¸µÈ Áø´Ü ÅøÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ÀÚ±Ý Áõ°¡, ±âÁõÀÚ Áö¿ø, 2, 3Â÷ º´¿øÀÇ ÀÎÇÁ¶ó ±¸ÃàÀº IVD Á¦Ç°ÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. º´¿ø ÇÁ·ÎÅäÄÝ¿¡ ü¿ÜÁø´Ü¿ë ÀǾàǰÀ» ÅëÇÕÇϸé ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ°í ºÒÇÊ¿äÇÑ Ç×»ýÁ¦ »ç¿ëÀ» ÁÙÀ̸ç, µµ½Ã ¹× ³óÃÌ º¸°Ç¼Ò¿¡¼­ÀÇ °¨¿° °ü¸®¸¦ È®½ÇÈ÷ °³¼±ÇÒ ¼ö ÀÖÀ¸¹Ç·Î °¨¿° ü¿ÜÁø´Ü¿ë ÀǾàǰ ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO) ¹× ¸ß½ÃÄÚ º¸°ÇºÎ ±¹¸³È£Èí±âÁúȯ¿¬±¸¼Ò´Â °¨¿°¼º ü¿ÜÁø´Ü ½ÃÀå º¸°í¼­ ÀÛ¼º½Ã Âü°íÇÑ 1Â÷ Á¤º¸ ¹× 2Â÷ Á¤º¸ Áß ÇϳªÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå °³¿ä

  • ¾Ö³Î¸®½ºÆ® ½ÃÀå Àü¸Á

Á¦3Àå Á¶»ç ¹æ¹ý

  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç
    • °¡¼³ Ã¥Á¤
    • °Å½Ã°æÁ¦ ¿äÀÎ ºÐ¼®
    • ±âÃÊ ¼öÄ¡ÀÇ °³¹ß
    • µ¥ÀÌÅÍ »ï°¢Ãø·®
    • ±¹°¡ ·¹º§ µ¥ÀÌÅÍ
  • °¡Á¤°ú ÇѰè

Á¦4Àå °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ±¸µµ

  • PEST ºÐ¼®

Á¦5Àå °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °¨¿°Áõ ÀÌȯÀ²ÀÇ Áõ°¡
    • ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ Àü·«Àû ¹ßÀü
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ºÒÃæºÐÇÑ »óȯ ½Ã³ª¸®¿À
  • ½ÃÀå ±âȸ
    • °¨¿°Áõ¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ Á¤ºÎ ±¸»ó
  • ÇâÈÄ µ¿Çâ
    • ±â¼úÀÇ Áøº¸
  • ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

  • °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ¸ÅÃâ, 2021-2031³â
  • °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ¿¹Ãø ºÐ¼®

Á¦7Àå °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ºÐ¼® - ¿ëµµº°

  • HIV ¶Ç´Â ¿¡ÀÌÁî
  • °áÇÙ
  • BÇü ¹× CÇü °£¿°
  • ¸»¶ó¸®¾Æ
  • ±âŸ

Á¦8Àå °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ºÐ¼® - ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø ¹× Áø·á¼Ò
  • Áø´Ü ¿¬±¸¼Ò
  • Ç÷¾×ÀºÇà
  • ±âŸ

Á¦9Àå °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå ºÐ¼® - Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±âŸ ±¹°¡
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Áß³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ Áß³²¹Ì

Á¦10Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ÀÇ Æ÷Áö¼Å´×°ú ÁýÁßµµ

Á¦11Àå ¾÷°è »óȲ

  • ¼¼°èÀÇ °¨¿°Áõ ü¿ÜÁø´Ü¾à ½ÃÀå¿¡¼­ ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦12Àå ±â¾÷ °³¿ä

  • ABBOTT LABORATORIES
  • F. HOFFMANN-LA ROCHE LTD
  • BECTON DICKINSON AND CO
  • SYSMEX CORP
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES INC
  • QIAGEN NV
  • QUIDELORTHO CORP
  • BRUKER CORP
  • DANAHER CORP

Á¦13Àå ºÎ·Ï

KSA 25.08.07

The infectious disease in vitro diagnostics market size is expected to grow from US$ 45.69 billion in 2024 to US$ 76.71 billion by 2031; it is projected to register a CAGR of 7.7% during 2025-2031. The increasing prevalence of infectious diseases and strategic developments by key players are noteworthy factors contributing to the expansion of the infectious disease in vitro diagnostics market size. However, the inadequate reimbursement scenario hinders the infectious disease in vitro diagnostics market growth.

Technological advancements involving the development and integration of molecular diagnostics and automation systems enhance the accuracy, speed, and accessibility of infectious disease detection. Below are a few instances:

In June 2024, MP Biomedicals introduced a new line of rapid immunochromatographic assays for Helicobacter pylori, Salmonella typhi, and Vibrio cholerae, intended for point-of-care in resource-constrained environments.

In June 2024, Roche gained FDA Emergency Use Authorization (EUA) for its cobas liat multiplex PCR panel updated to detect SARS-CoV-2, influenza A/B, and RSV simultaneously, advancing syndromic respiratory infection management in less than 20 minutes.

In July 2024, Sherlock Biosciences initiated clinical trials for its CRISPR-based over-the-counter (OTC) test for gonorrhea and chlamydia in May 2024, with an eye toward a 2025 launch. APEX-TB, integrating machine learning from AI and nanotechnology, was also launched to provide accurate, real-time molecular diagnostics using portable devices.

In June 2024, QIAGEN introduced 35 new wet-lab tested digital PCR Microbial DNA Detection Assays to its digital PCR (dPCR) platform QIAcuity, noticeably strengthening its capabilities in microbial research.

These advancements are part of a larger movement toward decentralized, user-centric, and fast diagnostic technologies guiding the future of infectious disease care. This is expected to contribute to the growth of the infectious disease in vitro diagnostics market in the coming years.

End User -Based Insights

Based on end user, the infectious disease in vitro diagnostics market is segmented into hospitals and clinics, diagnostics laboratories, blood bank, and others. The hospitals and clinics segment held the largest infectious disease in vitro diagnostics market share in 2024. The need for accurate, timely diagnosis in hospitals and clinics is rising steadily due to frequent outbreaks of Lassa fever, cholera, tuberculosis, and malaria. The soaring patient load and demand for quality care have pushed hospitals to adopt more sophisticated diagnostic tools, including molecular diagnostics. Increased government funding, donor support, and infrastructure improvements in secondary and tertiary hospitals further boost the adoption of IVD products. Integrating IVD in hospital protocols improves patient outcomes, reduces unnecessary antibiotic use, and ensures better management of infectious diseases in urban and rural health centers, thereby fueling the infectious disease in vitro diagnostics market growth.

The World Health Organization and Mexico's Ministry of Health's National Institute of Respiratory Diseases are among the primary and secondary sources referred to while preparing the infectious disease in vitro diagnostics market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Infectious Disease In vitro Diagnostics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Infectious Disease In vitro Diagnostics Market - Key Market Dynamics

  • 5.1 Infectious Disease In vitro Diagnostics Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Increasing Prevalence of Infectious Diseases
    • 5.2.2 Strategic Developments by Key Players
  • 5.3 Market Restraints
    • 5.3.1 Inadequate Reimbursement Scenario
  • 5.4 Market Opportunities
    • 5.4.1 Government Initiatives to Increase Awareness Regarding Infectious Diseases
  • 5.5 Future Trends
    • 5.5.1 Technological Advancements
  • 5.6 Impact of Drivers and Restraints:

6. Infectious Disease In vitro Diagnostics Market - Global Market Analysis

  • 6.1 Infectious Disease In vitro Diagnostics Market Revenue (US$ Million), 2021-2031
  • 6.2 Infectious Disease In vitro Diagnostics Market Forecast Analysis

7. Infectious Disease In vitro Diagnostics Market Analysis - by Applications

  • 7.1 HIV or AIDS
    • 7.1.1 Overview
    • 7.1.2 HIV or AIDS: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Tuberculosis
    • 7.2.1 Overview
    • 7.2.2 Tuberculosis: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Hepatitis B and C
    • 7.3.1 Overview
    • 7.3.2 Hepatitis B and C: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Malaria
    • 7.4.1 Overview
    • 7.4.2 Malaria: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)

8. Infectious Disease In vitro Diagnostics Market Analysis - by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Overview
    • 8.1.2 Hospitals and Clinics: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Overview
    • 8.2.2 Diagnostic Laboratories: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Blood Bank
    • 8.3.1 Overview
    • 8.3.2 Blood Bank: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast to 2031 (US$ Million)

9. Infectious Disease In vitro Diagnostics Market - Geographical Analysis

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 North America Infectious Disease In vitro Diagnostics Market Overview
    • 9.2.2 North America: Infectious Disease In vitro Diagnostics Market - Revenue, 2021-2031 (US$ Million)
      • 9.2.2.1 North America: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Applications
      • 9.2.2.2 North America: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.2.3 North America: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.2.3.1 United States: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.1.1 United States: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.2.3.1.2 United States: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.2.3.2 Canada: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.2.1 Canada: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.2.3.2.2 Canada: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.2.3.3 Mexico: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.3.1 Mexico: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.2.3.3.2 Mexico: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
  • 9.3 Europe
    • 9.3.1 Europe Infectious Disease In vitro Diagnostics Market Overview
    • 9.3.2 Europe: Infectious Disease In vitro Diagnostics Market - Revenue, 2021-2031 (US$ Million)
      • 9.3.2.1 Europe: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Applications
      • 9.3.2.2 Europe: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.3.3 Europe: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.3.3.1 United Kingdom: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.1.1 United Kingdom: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.3.3.1.2 United Kingdom: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.3.3.2 Germany: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.2.1 Germany: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.3.3.2.2 Germany: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.3.3.3 France: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.3.1 France: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.3.3.3.2 France: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.3.3.4 Italy: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.4.1 Italy: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.3.3.4.2 Italy: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.3.3.5 Spain: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.5.1 Spain: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.3.3.5.2 Spain: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.3.3.6 Rest of Europe: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.6.1 Rest of Europe: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.3.3.6.2 Rest of Europe: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Infectious Disease In vitro Diagnostics Market Overview
    • 9.4.2 Asia Pacific: Infectious Disease In vitro Diagnostics Market - Revenue, 2021-2031 (US$ Million)
      • 9.4.2.1 Asia Pacific: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Applications
      • 9.4.2.2 Asia Pacific: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.4.3 Asia Pacific: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 China: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.1.1 China: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.4.3.1.2 China: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.4.3.2 Japan: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.2.1 Japan: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.4.3.2.2 Japan: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.4.3.3 India: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.3.1 India: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.4.3.3.2 India: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.4.3.4 Australia: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.4.1 Australia: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.4.3.4.2 Australia: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.4.3.5 South Korea: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.5.1 South Korea: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.4.3.5.2 South Korea: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.4.3.6 Rest of APAC: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.6.1 Rest of APAC: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.4.3.6.2 Rest of APAC: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
  • 9.5 Middle East and Africa
    • 9.5.1 Middle East and Africa Infectious Disease In vitro Diagnostics Market Overview
    • 9.5.2 Middle East and Africa: Infectious Disease In vitro Diagnostics Market - Revenue, 2021-2031 (US$ Million)
      • 9.5.2.1 Middle East and Africa: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Applications
      • 9.5.2.2 Middle East and Africa: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.5.3 Middle East and Africa: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.5.3.1 South Africa: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.1.1 South Africa: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.5.3.1.2 South Africa: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.5.3.2 Saudi Arabia: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.2.1 Saudi Arabia: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.5.3.2.2 Saudi Arabia: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.5.3.3 United Arab Emirates: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.3.1 United Arab Emirates: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.5.3.3.2 United Arab Emirates: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.5.3.4 Rest of Middle East and Africa: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.4.1 Rest of Middle East and Africa: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.5.3.4.2 Rest of Middle East and Africa: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
  • 9.6 South and Central America
    • 9.6.1 South and Central America Infectious Disease In vitro Diagnostics Market Overview
    • 9.6.2 South and Central America: Infectious Disease In vitro Diagnostics Market - Revenue, 2021-2031 (US$ Million)
      • 9.6.2.1 South and Central America: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Applications
      • 9.6.2.2 South and Central America: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by End User
    • 9.6.3 South and Central America: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast Analysis - by Country
      • 9.6.3.1 Brazil: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.1.1 Brazil: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.6.3.1.2 Brazil: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.6.3.2 Argentina: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.2.1 Argentina: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.6.3.2.2 Argentina: Infectious Disease In vitro Diagnostics Market Breakdown, by End User
      • 9.6.3.3 Rest of South and Central America: Infectious Disease In vitro Diagnostics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.3.1 Rest of South and Central America: Infectious Disease In vitro Diagnostics Market Breakdown, by Applications
        • 9.6.3.3.2 Rest of South and Central America: Infectious Disease In vitro Diagnostics Market Breakdown, by End User

10. Competitive Landscape

  • 10.1 Heat Map Analysis by Key Players
  • 10.2 Company Positioning & Concentration

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Global Infectious Disease In-Vitro Diagnostics Market
  • 11.3 Organic Growth Strategies
    • 112.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 112.4.1 Overview

12. Company Profiles

  • 12.1. ABBOTT LABORATORIES
    • 12.1.1. Key Facts
    • 12.1.2. Business Description
    • 12.1.3. Products and Services
    • 12.1.4. Financial Overview
    • 12.1.5. SWOT Analysis
    • 12.1.6. Key Developments
  • 12.2. F. HOFFMANN-LA ROCHE LTD
    • 12.2.1. Key Facts
    • 12.2.2. Business Description
    • 12.2.3. Products and Services
    • 12.2.4. Financial Overview
    • 12.2.5. SWOT Analysis
    • 12.2.6. Key Developments
  • 12.3. BECTON DICKINSON AND CO
    • 12.3.1. Key Facts
    • 12.3.2. Business Description
    • 12.3.3. Products and Services
    • 12.3.4. Financial Overview
    • 12.3.5. SWOT Analysis
    • 12.3.6. Key Developments
  • 12.4. SYSMEX CORP
    • 12.4.1. Key Facts
    • 12.4.2. Business Description
    • 12.4.3. Products and Services
    • 12.4.4. Financial Overview
    • 12.4.5. SWOT Analysis
  • 12.5. BIOMERIEUX SA
    • 12.5.1. Key Facts
    • 12.5.2. Business Description
    • 12.5.3. Products and Services
    • 12.5.4. Financial Overview
    • 12.5.5. SWOT Analysis
    • 12.5.6. Key Developments
  • 12.6. BIO-RAD LABORATORIES INC
    • 12.6.1. Key Facts
    • 12.6.2. Business Description
    • 12.6.3. Products and Services
    • 12.6.4. Financial Overview
    • 12.6.5. SWOT Analysis
    • 12.6.6. Key Developments
  • 12.6. QIAGEN NV
    • 12.6.1. Key Facts
    • 12.6.2. Business Description
    • 12.6.3. Products and Services
    • 12.6.4. Financial Overview
    • 12.6.5. SWOT Analysis
    • 12.6.6. Key Developments
  • 12.8. QUIDELORTHO CORP
    • 12.8.1. Key Facts
    • 12.8.2. Business Description
    • 12.8.3. Products and Services
    • 12.8.4. Financial Overview
    • 12.8.5. SWOT Analysis
    • 12.8.6. Key Developments
  • 12.9. BRUKER CORP
    • 12.9.1. Key Facts
    • 12.9.2. Business Description
    • 12.9.3. Products and Services
    • 12.9.4. Financial Overview
    • 12.9.5. SWOT Analysis
    • 12.9.6. Key Developments
  • 12.10. DANAHER CORP
    • 12.10.1. Key Facts
    • 12.10.2. Business Description
    • 12.10.3. Products and Services
    • 12.10.4. Financial Overview
    • 12.10.5. SWOT Analysis
    • 12.10.6. Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦